Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEPPRA XR vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Adjunctive therapy for partial-onset seizures in adults and children aged ≥4 years,Adjunctive therapy for myoclonic seizures in adults and adolescents aged ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children aged ≥6 years with idiopathic generalized epilepsy
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Metabolized primarily by hydrolysis of the acetamide group via enzymatic hydrolysis (not CYP450 dependent); forms inactive metabolite (UCB L057); ~24% of dose undergoes oxidative metabolism.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
<10%; binding to albumin (not extensive).
16% (primarily albumin).
0.5–0.7 L/kg; suggests distribution into total body water.
3.2-5.6 L/kg; indicates extensive tissue distribution.
100% for oral tablet (immediate-release); 100% for extended-release (relative to immediate-release).
Oral IR: ~90%; ER: ~90%.
For Cr Cl > 80 m L/min: 1500 mg once daily; Cr Cl 50-80 m L/min: 1000 mg once daily; Cr Cl 30-49 m L/min: 500 mg once daily; Cr Cl < 30 m L/min: 250 mg once daily. ESRD on dialysis: 500 mg once daily with 250 mg supplemental dose post-dialysis.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
For children ≥12 years (≥40 kg): 1500 mg orally once daily. Not FDA-approved for <12 years; use immediate-release formulation for pediatric patients <12 years: starting dose 10 mg/kg twice daily, titrated to 30 mg/kg twice daily.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
Elderly patients often have reduced creatinine clearance; dose should be adjusted based on renal function. Monitor for drowsiness, dizziness, and ataxia. Start at lower end of dosing range and titrate cautiously.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
No FDA black box warning.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Behavioral abnormalities including psychosis, aggression, hostility, irritability, and suicidal ideation/behavior,Somnolence and fatigue,Serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (decreased red blood cell, white blood cell, and platelet counts),Increased blood pressure in pediatric patients,Withdrawal seizures upon abrupt discontinuation
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Hypersensitivity to levetiracetam or any component of the formulation
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
No significant food interactions. Grapefruit juice does not affect levetiracetam. Avoid alcohol as it may exacerbate CNS depression.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy association unclear but may be dose-dependent. Second/third trimester: Risk of fetal growth restriction, hemorrhagic disease of newborn (vitamin K deficiency due to enzyme induction). Perinatal: Neonatal withdrawal syndrome, sedation, and coagulopathy.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Levetiracetam is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is low (2–7% of weight-adjusted maternal dose). Limited data suggest no adverse effects in breastfed infants, but monitor for drowsiness, poor feeding. Benefit likely outweighs risk in most cases.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
Increased clearance of levetiracetam during pregnancy, particularly in the second and third trimesters (up to 50–60% higher). Dose adjustments may be required to maintain therapeutic trough levels (target 12–46 µg/m L). Consider therapeutic drug monitoring every 1–3 months and after delivery, with gradual dose reduction to pre-pregnancy levels within 1–2 weeks postpartum.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
Keppra XR (levetiracetam extended-release) is dosed once daily due to its prolonged absorption profile. Therapeutic drug monitoring is not routinely required because of its predictable pharmacokinetics and wide therapeutic index. Adjust dose in renal impairment (Cr Cl < 80 m L/min) using ideal body weight; supplement dose after hemodialysis. May cause somnolence, dizziness, and behavioral changes (e.g., aggression, psychosis) especially in pediatric and elderly patients. Stevens-Johnson syndrome and angioedema are rare but serious adverse effects. Sudden discontinuation may precipitate withdrawal seizures; taper over at least 2 weeks.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Take exactly as prescribed once daily with or without food, at the same time each day.,Swallow tablet whole; do not crush, chew, or break.,Do not drive or operate heavy machinery until you know how this medicine affects you.,Contact your doctor immediately if you experience skin rash, blistering, swelling of face/lips, or difficulty breathing.,Inform your doctor of any history of depression, mood swings, aggressive behavior, or suicidal thoughts.,Report any worsening of seizures or new types of seizures.,If you are on dialysis, take the recommended supplement dose after each session.,Do not stop taking this medicine suddenly as it may cause withdrawal seizures.,Avoid alcohol while taking Keppra XR; it may increase drowsiness and dizziness.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEPPRA XR vs ADDERALL 20, answered by our medical review team.
KEPPRA XR is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEPPRA XR and ADDERALL 20 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEPPRA XR is: 1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEPPRA XR and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEPPRA XR is classified as Category C. Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy a. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.